Publication

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.

Journal Paper/Review - Jan 9, 2024

Rastogi Priya, O'Shaughnessy Joyce, Martín Miguel, Boyle Frances, Cortes Javier, Rugo Hope S, Goetz Matthew P, Hamilton Erika, Huang Chiun-Sheng, Senkus Elzbieta, Tryakin Alexey, Cicin Irfan, Testa Laura, Neven Patrick, Huober Jens, Shao Zhimin, Wei Ran, Andre Valerie A M, Munoz Maria, San Antonio Belen, Shahir Ashwin, Harbeck Nadia, Johnston Stephen R D